Soly Ismail

Oncogenic RAS mutations result in the constant activation of downstream pathways such as those controlled by P-I3K and RAF protein kinases - which are associated with various types of cancer. My aim is to discover and characterise specific inhibitors that could block the RAS/P-I3K and RAS/RAF for future targeted therapies.